U.S. Markets open in 3 hrs 15 mins

Allergan plc (AGN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
249.07+2.66 (+1.08%)
At close: 4:03PM EDT
People also watch
BIIBCELGVRXGILDREGN

Allergan plc

Clonshaugh Business and Technology Park
Coolock
Dublin D17 E400
Ireland
862 261 7000
http://www.allergan.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees16,700

Key Executives

NameTitlePayExercisedAge
Mr. Brenton L. Saunders J.D.Chairman, Chief Exec. Officer and Pres4.14MN/A47
Ms. Maria Teresa HiladoChief Financial Officer and Exec. VP1.26MN/A52
Mr. Robert A. StewartExec. VP & Chief Operating Officer1.49MN/A49
Mr. William MeuryChief Commercial Officer and Exec. VP1.69M936.88k49
Mr. James C. D'AreccaChief Accounting Officer and VPN/AN/A46
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Corporate Governance

Allergan plc’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.